Cargando…

Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis

Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Field, Des, Considine, Kiera, O’Connor, Paula M., Ross, R. Paul, Hill, Colin, Cotter, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036683/
https://www.ncbi.nlm.nih.gov/pubmed/33801752
http://dx.doi.org/10.3390/ijms22073480
_version_ 1783676967712718848
author Field, Des
Considine, Kiera
O’Connor, Paula M.
Ross, R. Paul
Hill, Colin
Cotter, Paul D.
author_facet Field, Des
Considine, Kiera
O’Connor, Paula M.
Ross, R. Paul
Hill, Colin
Cotter, Paul D.
author_sort Field, Des
collection PubMed
description Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly directed to veterinary applications, do not require a lengthy milk withholding period and that will not have a negative impact on the growth of lactic acid bacteria involved in downstream dairy fermentations. Nisin is the prototypical lantibiotic, a family of highly modified antimicrobial peptides that exhibit potent antimicrobial activity against many Gram-positive microbes, including human and animal pathogens including species of Staphylococcus and Streptococcus. Although not yet utilized in the area of human medicine, nisin is currently applied as the active agent in products designed to prevent bovine mastitis. Over the last decade, we have harnessed bioengineering strategies to boost the specific activity and target spectrum of nisin against several problematic microorganisms. Here, we screen a large bank of engineered nisin derivatives to identify novel derivatives that exhibit improved specific activity against a selection of staphylococci, including mastitis-associated strains, but have unchanged or reduced activity against dairy lactococci. Three such peptides were identified; nisin A M17Q, nisin A T2L and nisin A HTK.
format Online
Article
Text
id pubmed-8036683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80366832021-04-12 Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis Field, Des Considine, Kiera O’Connor, Paula M. Ross, R. Paul Hill, Colin Cotter, Paul D. Int J Mol Sci Article Bovine mastitis is a significant economic burden for dairy enterprises, responsible for premature culling, prophylactic and therapeutic antibiotic use, reduced milk production and the withholding (and thus wastage) of milk. There is a desire to identify novel antimicrobials that are expressly directed to veterinary applications, do not require a lengthy milk withholding period and that will not have a negative impact on the growth of lactic acid bacteria involved in downstream dairy fermentations. Nisin is the prototypical lantibiotic, a family of highly modified antimicrobial peptides that exhibit potent antimicrobial activity against many Gram-positive microbes, including human and animal pathogens including species of Staphylococcus and Streptococcus. Although not yet utilized in the area of human medicine, nisin is currently applied as the active agent in products designed to prevent bovine mastitis. Over the last decade, we have harnessed bioengineering strategies to boost the specific activity and target spectrum of nisin against several problematic microorganisms. Here, we screen a large bank of engineered nisin derivatives to identify novel derivatives that exhibit improved specific activity against a selection of staphylococci, including mastitis-associated strains, but have unchanged or reduced activity against dairy lactococci. Three such peptides were identified; nisin A M17Q, nisin A T2L and nisin A HTK. MDPI 2021-03-27 /pmc/articles/PMC8036683/ /pubmed/33801752 http://dx.doi.org/10.3390/ijms22073480 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Field, Des
Considine, Kiera
O’Connor, Paula M.
Ross, R. Paul
Hill, Colin
Cotter, Paul D.
Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title_full Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title_fullStr Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title_full_unstemmed Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title_short Bio-Engineered Nisin with Increased Anti-Staphylococcus and Selectively Reduced Anti-Lactococcus Activity for Treatment of Bovine Mastitis
title_sort bio-engineered nisin with increased anti-staphylococcus and selectively reduced anti-lactococcus activity for treatment of bovine mastitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036683/
https://www.ncbi.nlm.nih.gov/pubmed/33801752
http://dx.doi.org/10.3390/ijms22073480
work_keys_str_mv AT fielddes bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis
AT considinekiera bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis
AT oconnorpaulam bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis
AT rossrpaul bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis
AT hillcolin bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis
AT cotterpauld bioengineerednisinwithincreasedantistaphylococcusandselectivelyreducedantilactococcusactivityfortreatmentofbovinemastitis